
|Videos|January 19, 2016
- NSCLC (Issue 10)
- Volume 10
- Issue 10
Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC
Author(s)Renato G. Martins, MD, MPH
​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non
Renato G. Martins, MD, MPH, Medical Director, Thoracic/Head and Neck Medical Oncology, Seattle Cancer Care Alliance, discusses nivolumab in nonsmall cell lung cancer (NSCLC). Martins says while there are a number of trials where nivolumab is being combined with chemotherapy to increase its efficacy, the treatment is not ready for the firstline. He says until there is a reliable biomarker to identify which patients would benefit from the treatment, it would be difficult to move nivolumab into the frontline.
Articles in this issue
almost 10 years ago
Research Team Challenges Plant-Derived Molecule for the Treatment of NSCLCalmost 10 years ago
Combining Immunotherapy With Anti-VEGF Agents Rigorously Explored in NSCLCalmost 10 years ago
Lung Cancer Research Shows Distinct Genomic Differences in Younger Patients



































